Q4 and FY 2025 results Continuously delivering solid profitable growth February 4, 2026 Forward looking and intended use statements Safe Harbor Statement: Certain statements contained in this presentation may be considered forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended, and Section 21E of the U.S. Securities Exchange Act of 1934, as amended. These statements can be identified by the use of forward-looking terminology such as "believe", "hope", "pl ...

Core Insights - Evogene Ltd. and Lishan Biotech have entered into an exclusive worldwide licensing agreement for BMC128, a microbiome-based therapeutic aimed at enhancing anti-tumor immune activity, which is currently completing Phase 1 clinical studies with promising early results [1][3]. Company Overview - Evogene Ltd. specializes in computational chemistry and generative design of small molecules for pharmaceutical and agricultural industries, utilizing its proprietary ChemPass AI™ technology to improve success rates and reduce development time and costs [5][6]. - Lishan Biotech focuses on innovative therapies for complex chronic diseases, employing unique technologies to address gut microbial colonization and developing microbiome-based therapies for oncology and other conditions [7]. Clinical Development - BMC128 is a live biopharmaceutical consortium composed of four human gut bacterial strains that enhance responses to immunotherapy, currently being studied in renal cell carcinoma and non-small cell lung cancer, showing an excellent safety profile and early signs of efficacy [2][3]. - Under the licensing agreement, Lishan Biotech will manage global clinical development, manufacturing, and commercialization of BMC128, with Biomica eligible for milestone payments and royalties [3]. Future Plans - Lishan Biotech intends to advance BMC128 into Phase 2 clinical studies and pursue regulatory filings in both China and the United States for commercialization [3]. - The collaboration aims to leverage Lishan Biotech's development capabilities and Evogene's innovation in microbiome science to create value in difficult-to-treat cancers [4].

Qiagen (QGEN) reported $540.42 million in revenue for the quarter ended December 2025, representing a year-over-year increase of 3.7%. EPS of $0.62 for the same period compares to $0.64 a year ago.The reported revenue represents a surprise of +2.36% over the Zacks Consensus Estimate of $527.96 million. With the consensus EPS estimate being $0.62, the EPS surprise was +0.83%.While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine ...

VANCOUVER, BC / ACCESS Newswire / February 4, 2026 / Onco-Innovations Limited (CBOE CA:ONCO)(OTCQB:ONNVF)(Frankfurt:W1H, WKN:A3EKSZ) ("Onco" or the "Company") announces that it has filed a preliminary base shelf prospectus dated February 3, 2026 (the "Base Shelf Prospectus") with the securities regulatory authorities in each of the provinces of Alberta, British Columbia, Manitoba and Ontario. The Base Shelf Prospectus has been filed, but is not yet final, and the securities described therein may not be s ...

Financial Data and Key Metrics Changes - The company reported record fourth quarter revenues of $488 million, an increase of 11% compared to the prior year period [10] - For the full year, adjusted revenues grew 28% to $1.54 billion, driven by a 35% increase in M&A activities [4][10] - Adjusted EPS for the full year was $2.99 per share, representing a 64% increase from $1.82 per share in 2024 [12] - The adjusted compensation ratio improved by 320 basis points to 65.8% for the full year [9][10] Business Line Data and Key Metrics Changes - M&A accounted for approximately two-thirds of the business mix for both the fourth quarter and full year, with significant growth in capital markets [10] - Capital Structure Advisory (CSA) saw a decline, while M&A and Capital Markets revenues increased [10][68] - The private capital advisory (PCA) business is ramping up, with expectations for more meaningful revenue growth in 2026 [68] Market Data and Key Metrics Changes - The company noted an increase in investor appetite across growth-oriented sectors, contributing to a constructive financing market [5] - The M&A market is expected to broaden across transaction sizes as confidence in larger transformational deals grows [5][26] Company Strategy and Development Direction - The company aims to continue investing in its private capital advisory business, which is seen as an increasingly important pillar [8] - There is a focus on enhancing capabilities in capital structure advisory and liability management, anticipating a long runway of activity due to high leverage across many companies [6][21] - The company is well-positioned to capitalize on the growing demand for GP-led secondaries and restructuring assignments [18][21] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the transaction environment in 2026, citing strong client activity and a robust pipeline [4][9] - The company is confident in its ability to drive growth while generating operating leverage and delivering sustained value [9] - Management acknowledged the potential impact of geopolitical factors on transaction activities but noted that companies are adapting to uncertainties [30][31] Other Important Information - The board declared a regular quarterly dividend of $0.65 per share and authorized a new share repurchase program of up to $300 million [13][70] - The company maintains a strong balance sheet with $849 million in cash and no debt [13] Q&A Session Summary Question: Broader advisory outlook and sponsor engagement - Management noted an increasing velocity of sponsor deals and expects more activity in the middle market in 2026 [17] Question: Restructuring liability management activity - Management indicated a long runway of companies needing liability management due to high leverage and technology disruption [20] Question: M&A composition and outlook for 2026 - Management expects continued activity in larger transactions while anticipating a resurgence in middle-market deals as financing conditions improve [26][28] Question: Impact of geopolitical factors on transactions - Management acknowledged that geopolitical uncertainties can affect transaction activities but noted that companies are becoming more accustomed to these fluctuations [30][31] Question: Revenue recognition and cadence for 2026 - Management expressed optimism about a constructive environment for transactions, although predicting specific quarterly revenues remains challenging [35] Question: Compensation ratio expectations for 2026 - Management anticipates starting the year with a similar compensation ratio to the previous year, around 65.8% [79]

Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Vistagen (VTGN) To Contact Him Directly To Discuss Their Options If you purchased or acquired Vistagen common stock between April 1, 2024 and December 16, 2025 and would like to discuss your legal rights, call Bragar Eagel & Squire partner Brandon Walker or Melissa Forunato directly at (212) 355-4648. Click here to participate in the action. NEW YORK, Feb. 04, 2026 (GLOBE NEWSWIRE) -- What’s Happening: ...

Veracyte to Release Fourth Quarter and Full-Year 2025 Financial Results on February 25, 2026-# Veracyte to Release Fourth Quarter and Full-Year 2025 Financial Results on February 25, 2026Share---SOUTH SAN FRANCISCO, Calif.--([BUSINESS WIRE])-- [Veracyte, Inc.](Nasdaq: VCYT), a leading cancer diagnostics company, announced today that it will release financial results for the fourth quarter and full-year 2025 after the close of market on Wednesday, February 25, 2026. Company management will host a conference ...

NEW YORK, Feb. 04, 2026 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Vistagen Therapeutics, Inc. (NASDAQ: VTGN). Shareholders who purchased shares of VTGN during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/vistagen-therapeutics-inc-loss-submission-form/?id=183336&from=3 CLASS ...

New York, New York--(Newsfile Corp. - February 4, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Alvotech (NASDAQ: ALVO) resulting from allegations that Alvotech may have issued materially misleading business information to the investing public.SO WHAT: If you purchased Alvotech securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangem ...

REDWOOD CITY, Calif., Feb. 04, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced that Mark A. Goldsmith, M.D., Ph.D., the company’s chief executive officer and chairman, will participate in a fireside chat as part of the Guggenheim Securities Emerging Outlook: Biotech Summit 2026 on Wednesday, February 11 at 9:30 a.m. ET. To listen to a live webcast of this event, or ...